Anzeige
Mehr »
Login
Freitag, 18.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Forge bereits +300 %
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Edison Investment Research-Archiv vom 20.02.2025

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
20.02.IRLAB Therapeutics - EMA alignment on mesdopetam Phase III plans350IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European Medicines Agency (EMA) is aligned with the company...
► Artikel lesen
20.02.Metlen (ASE: MYTIL) FY24 Results263Metlen's FY24 results released on 20 February were broadly in line with consensus (EBITDA €1,080bn, 0.9% above consensus of €1,070bn and 2.4% above Edison of €1055bn, EPS €4.46, 2.2% below consensus...
► Artikel lesen
20.02.Mendus - Vididencel on track in AML going into 2025274Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the...
► Artikel lesen
20.02.Recce Pharmaceuticals - Positive R327G Phase II ABSSSI study results357Recce has reported positive results from its open-label Phase II study assessing RECCE® 327 topical gel (R327G) in patients with acute bacterial skin and skin structure infections (ABSSSI), including...
► Artikel lesen